Targeting CD177: A Novel Therapeutic Strategy for NLRP3-Associated Autoinflammatory Diseases

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• NLRP3-associated autoinflammatory diseases (NLRP3-AIDs) stem from excessive inflammasome activation.
• Current IL-1β blockade therapy shows inadequate response in many patients, necessitating alternative treatments.

Purpose of the Study:

• To investigate CD177 as a downstream effector of NLRP3 activation.
• To establish and utilize a novel NLRP3 L573W knock-in mouse model for disease study.
• To evaluate CD177 silencing as a therapeutic strategy for NLRP3-AIDs.

Main Methods:

• Transcriptomic analysis of immune cells from an NLRP3 L573W patient.
• Functional validation of CD177's role in NLRP3 activation.
• Development of an NLRP3 L573W knock-in mouse model.
• Assessment of CD177 expression correlation with disease parameters.
• Evaluation of siRNA-mediated CD177 silencing efficacy versus IL-1β blockade.

Main Results:

• CD177, a neutrophil protein, is upregulated in NLRP3-mutant cells and directly downstream of NLRP3 activation.
• The NLRP3 L573W mouse model demonstrated variable disease severity, mirroring human heterogeneity.
• CD177 expression positively correlated with disease severity, neutrophilia, and tissue damage.
• CD177 silencing reduced inflammation, neutrophil infiltration, and cytokine levels, ameliorating organ damage.

Conclusions:

• CD177 acts as a non-canonical amplifier of NLRP3-driven inflammation.
• Targeting CD177 presents a promising therapeutic approach for NLRP3-AIDs, including refractory cases.
• CD177 silencing demonstrated comparable or superior efficacy to IL-1β blockade in preclinical models.